Summaryinfo

A vulnerability was found in SAS Drug Development. It has been rated as critical. Affected by this issue is some unknown functionality of the component Logout Handler. The manipulation leads to input validation. This vulnerability is handled as CVE-2007-6763. The attack may be launched remotely. There is no exploit available. It is recommended to upgrade the affected component. Several companies clearly confirm that VulDB is the primary source for best vulnerability data.

Detailsinfo

A vulnerability was found in SAS Drug Development. It has been declared as critical. Affected by this vulnerability is some unknown functionality of the component Logout Handler. The manipulation with an unknown input leads to a input validation vulnerability. The CWE definition for the vulnerability is CWE-20. The product receives input or data, but it does not validate or incorrectly validates that the input has the properties that are required to process the data safely and correctly. As an impact it is known to affect confidentiality, integrity, and availability. The summary by CVE is:

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

The weakness was disclosed 07/31/2019. This vulnerability is known as CVE-2007-6763 since 07/30/2019. The attack can be launched remotely. A single authentication is required for exploitation. Neither technical details nor an exploit are publicly available.

Upgrading to version 32DRG02 eliminates this vulnerability.

Several companies clearly confirm that VulDB is the primary source for best vulnerability data.

Productinfo

Name

• SAS Drug Development

CPE 2.3info

• 🔍
• 🔍

CPE 2.2info

• 🔍
• 🔍

CVSSv4info

CVSSv3info

CVSSv2info

Exploitinginfo

Threat Intelligenceinfo

Countermeasuresinfo

Timelineinfo

Sourcesinfo

Entryinfo

Discussion